Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results

ReShape Lifesciences Inc. (OBLN) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
10/05/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "Form of Placement Agent Warrant (filed herewith)",
"ReShape Lifesciences Announces Pricing of $3.0 Million Public Offering"
10/03/2023 424B4 Form 424B4 - Prospectus [Rule 424(b)(4)]:
10/02/2023 EFFECT Form EFFECT - Notice of Effectiveness:
09/27/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
08/25/2023 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 8-K Quarterly results
07/19/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/06/2023 4 STANKOVICH THOMAS (CFO) has filed a Form 4 on ReShape Lifesciences Inc.
Txns: Sold 109 shares @ $2.6, valued at $283.4
Sold 96 shares @ $2.36, valued at $226.6
Sold 98 shares @ $2.41, valued at $236.2
Bought 17,702 shares @ $1.52, valued at $26.9k
05/15/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/26/2023 8-K Quarterly results
04/24/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
04/17/2023 10-K Annual Report for the period ended December 31, 2022
04/13/2023 8-K Quarterly results
04/03/2023 NT 10-K Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405:
03/21/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
03/17/2023 SC 13D Matthew Joseph Nachtrab Revocable Trust 2014 reports a 27.7% stake in RESHAPE LIFESCIENCES INC.
03/07/2023 4 STANKOVICH THOMAS (CFO) has filed a Form 4 on ReShape Lifesciences Inc.
Txns: Sold 48 shares @ $7.49, valued at $359.5
Sold 110 shares @ $7.4906, valued at $824
Sold 157 shares @ $13.29, valued at $2.1k
Sold 103 shares @ $4.25, valued at $437.8
02/14/2023 SC 13G/A ARMISTICE CAPITAL, LLC reports a 5% stake in RESHAPE LIFESCIENCES INC.
02/10/2023 8-K Quarterly results
02/08/2023 424B4 Form 424B4 - Prospectus [Rule 424(b)(4)]:
02/06/2023 EFFECT Form EFFECT - Notice of Effectiveness:
02/03/2023 S-1MEF Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)]:
02/03/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
02/02/2023 RW Form RW - Registration Withdrawal Request:
02/02/2023 RW Form RW - Registration Withdrawal Request:
01/27/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BUSINESS Our Company ReShape Lifesciences Inc. is a worldwide premier weight-loss solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. Our current portfolio includes the FDA-approved Lap-Band system, which provides minimally invasive, long-term treatment of obesity and is a safer surgical alternative to more invasive and extreme surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. The recently launched ReShapeCare TM virtual health coaching program is a novel reimbursed telehealth weight-management program that supports healthy lifestyle changes for all medically managed weight-loss patients, not just the Lap-Band, further expanding our reach and market opportunity. The ReShape Mar...",
"RISK FACTORS"
01/12/2023 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
12/28/2022 8-K Quarterly results
12/20/2022 8-K Quarterly results
12/20/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/14/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/14/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy